Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002385444 | SCV002694333 | pathogenic | Cardiovascular phenotype | 2017-05-24 | criteria provided, single submitter | clinical testing | The c.1311+2T>G intronic pathogenic mutation results from a T to G substitution two nucleotides after coding exon 10 in the ENG gene. This mutation was identified in an individual meeting diagnostic criteria of hereditary hemorrhagic telangiectasia (HHT) (McDonald J et al. Clin. Genet., 2011 Apr;79:335-44). Other nucleotide substitutions at the same position were also reported in individuals with HHT (Cymerman U et al. Pediatr. Res., 2000 Jan;47:24-35; Bossler AD et al. Hum. Mutat., 2006 Jul;27:667-75). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. |